Telix Pharmaceuticals Stock Debt To Equity
TLX Stock | 25.74 0.80 3.21% |
Telix Pharmaceuticals fundamentals help investors to digest information that contributes to Telix Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Telix Stock. The fundamental analysis module provides a way to measure Telix Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Telix Pharmaceuticals stock.
Telix | Debt To Equity |
Telix Pharmaceuticals Company Debt To Equity Analysis
Telix Pharmaceuticals' Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
Competition |
Telix Total Stockholder Equity
Total Stockholder Equity |
|
According to the company disclosure, Telix Pharmaceuticals has a Debt To Equity of 0.0%. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all Australia stocks average (which is currently at 0.0).
Did you try this?
Run Portfolio Optimization Now
Portfolio OptimizationCompute new portfolio that will generate highest expected return given your specified tolerance for risk |
All Next | Launch Module |
Telix Fundamentals
Return On Equity | 0.2 | ||||
Return On Asset | 0.0797 | ||||
Profit Margin | 0.08 % | ||||
Operating Margin | 0.09 % | ||||
Current Valuation | 8.52 B | ||||
Shares Outstanding | 334.72 M | ||||
Shares Owned By Insiders | 41.42 % | ||||
Shares Owned By Institutions | 17.88 % | ||||
Price To Book | 21.33 X | ||||
Price To Sales | 13.01 X | ||||
Revenue | 496.66 M | ||||
Gross Profit | 98.54 M | ||||
EBITDA | 22.97 M | ||||
Net Income | 5.21 M | ||||
Total Debt | 17.45 M | ||||
Book Value Per Share | 1.21 X | ||||
Cash Flow From Operations | 23.88 M | ||||
Earnings Per Share | 0.15 X | ||||
Target Price | 25.62 | ||||
Beta | 2.38 | ||||
Market Capitalization | 8.4 B | ||||
Total Asset | 398.3 M | ||||
Retained Earnings | (263.67 M) | ||||
Working Capital | 67.44 M | ||||
Net Asset | 398.3 M |
About Telix Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Telix Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Telix Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Telix Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Telix Stock Analysis
When running Telix Pharmaceuticals' price analysis, check to measure Telix Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Telix Pharmaceuticals is operating at the current time. Most of Telix Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Telix Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Telix Pharmaceuticals' price. Additionally, you may evaluate how the addition of Telix Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.